You are about to leave a GSK website. By clicking this link, you will be taken to a website that is independent from GSK. The site you are linking to is not controlled or endorsed by GSK, and GSK is not responsible for the content provided on that site.
ANORO is for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). ANORO is NOT for the relief of acute bronchospasm or for asthma.
ANORO is for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
ANORO is NOT for the relief of acute bronchospasm or for asthma.
ANORO is for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
ANORO is NOT for the relief of acute bronchospasm or for asthma.
CONTRAINDICATIONS
CONTRAINDICATIONS
WARNINGS AND PRECAUTIONS
ADVERSE REACTIONS
DRUG INTERACTIONS
CI=confidence interval; COPD=chronic obstructive pulmonary disease; FEV1=forced expiratory volume in 1 second; GOLD=Global Initiative for Chronic Obstructive Lung Disease; ICS=inhaled corticosteroid; LABA=long-acting beta2-adrenergic agonist; LAMA=long-acting muscarinic antagonist; LS=least squares; OR=odds ratio; QOL =quality of life; UMEC=umeclidinium; VI=vilanterol.
To report SUSPECTED ADVERSE REACTIONS, contact GSK at 1-888-825-5249 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.